Scarica l'app Stockscreener
7.195
5.08%
-0.385
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com
mRNA drug developer Arcturus set for Leerink healthcare fireside chat - Stock Titan
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey
ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat
Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka
Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com
Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st
Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat
Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus
Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus
New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com
Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat
Arcturus Therapeutics reports financial results and pipeline progress - Traders Union
Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Arcturus Q4 2025 misses expectations, stock drops - Investing.com South Africa
Arcturus Therapeutics Q4 Earnings Call Highlights - MarketBeat
ARCTURUS THERAPEUTICS ($ARCT) Releases Q4 2025 Earnings - Quiver Quantitative
Arcturus (ARCT) Faces Shortfall in Q4 Revenue, Focuses on New Th - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates By Investing.com - Investing.com Canada
Arcturus Therapeutics (NASDAQ:ARCT) Releases Earnings Results, Misses Estimates By $0.11 EPS - MarketBeat
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Arcturus Therapeutics Holdings Inc earnings missed by $5.31, revenue fell short of estimates - Investing.com India
Arcturus Therapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arcturus Therapeutics falls 5% on weak quarterly revenue By Investing.com - Investing.com Nigeria
Arcturus Therapeutics falls 5% on weak quarterly revenue - Investing.com South Africa
Arcturus Therapeutics 10-K: Revenue $82.0M; EPS not reported - TradingView
KOSTAIVE setback and mRNA pipeline progress at Arcturus (NASDAQ: ARCT) - Stock Titan
Arcturus Therapeutics (ARCT) trims 2025 loss and extends cash runway into Q2 2028 - Stock Titan
Arcturus Therapeutics Q4 Earnings Assessment - Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress - Yahoo Finance
Precision Trading with Arcturus Therapeutics Holdings Inc. (ARCT) Risk Zones - Stock Traders Daily
What To Expect From Arcturus Therapeutics Holdings Inc (ARCT) Q4 2025 Earnings - GuruFocus
Earnings Preview: Arcturus Therapeutics - Sahm
Momentum Shift: How liquid is Arcturus Therapeutics Holdings Inc stockJuly 2025 Weekly Recap & Real-Time Buy Signal Notifications - baoquankhu1.vn
Bethany Children's Health Center unveils immersive experience plans - AOL.com
Arcturus Therapeutics Holdings Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
Arcturus Therapeutics (ARCT) Stock Analysis: Exploring a 304% Potential Upside Amidst Clinical Pipeline Advances - DirectorsTalk Interviews
Arcturus Therapeutics (ARCT) Expected to Post Earnings on Tuesday - MarketBeat
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Potential 346% Upside with Innovative mRNA Therapies - DirectorsTalk Interviews
Technical Reactions to ARCT Trends in Macro Strategies - Stock Traders Daily
Roth Capital Say Market Pricing Implies Zero Success for Arcturus Therapeutics Holdings Inc. (ARCT) Pipeline Assets - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Crosses Below Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Volatility Watch: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesMarket Growth Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026 - BioSpace
Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Co - PharmiWeb.com
Balyasny reports no Arcturus Therapeutics (ARCT) stake in amended 13G/A - Stock Titan
Citi lowers price target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, maintains neutral rating - MSN
Is Arcturus Therapeutics Holdings (NASDAQ:ARCT) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Arcturus cut to Neutral at Citi on data for mRNA candidate - MSN
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A Biotech Gem with 353% Upside Potential? - DirectorsTalk Interviews
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure - Seeking Alpha
Is Arcturus Therapeutics Holdings Inc. stock a buy before product launches - mfd.ru
Arcturus at Guggenheim Biotech Summit: Strategic Advances in mRNA Therapies - Investing.com Canada
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit - MarketBeat
ARCT: Pivotal phase IIb CF trial and key regulatory meetings for OTC deficiency set for early 2024 - TradingView
Citi Lowers Price Target on Arcturus Therapeutics Holdings Inc. (ARCT) to $7, Maintains Neutral Rating - Finviz
3.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):